Press Release Archive

(BUSINESS WIRE)--Pfizer announced today updated safety and efficacy results surrounding its investigational compound, CP-751,871, in patients with non-small cell lung cancer (NSCLC). These results, along with supporting correlative science data, were presented at the 33rd European Society for Medical Oncology (ESMO) congress in Stockholm, Sweden. Results from a Phase II, randomized, non-comparative study, “Addition

(BUSINESS WIRE)--Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA). Following feedback from regulatory authorities, the company plans to conduct an additional Phase 3 clinical trial with dalbavancin for the

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, President, Worldwide Pharmaceutical Operations, at the UBS Global Life Sciences Conference on Monday, September 22 at 2:00 p.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “UBS Global Life Sciences Conference

(BUSINESS WIRE)--Pfizer announced that in patients with established heart disease, Lipitor® (atorvastatin calcium) 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg but also provided a sustained reduction in the risk of a subsequent second, third, fourth, and fifth cardiovascular event, according to a subanalysis of the five-year Treating to New Targets

(BUSINESS WIRE)--Pfizer Inc said today that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company’s favor in challenges to two of its patents covering atorvastatin, the active ingredient in Lipitor. The basic (DK 171,588) and enantiomer (EP 409,281) patents were challenged by generics manufacturer Ranbaxy. The court ruled that the basic patent, which expires in November 2011, would be infringed

(BUSINESS WIRE)--With canine motion sickness the leading reason pet owners are not able to take their dogs on day trips or vacation, Pfizer is encouraging more people to talk with their veterinarians about managing travel with their dog before the summer ends. Since Pfizer’s Cerenia™ (maropitant citrate) became the first-and-only veterinary approved canine medication in America, Europe and Canada to prevent vomiting from

(BUSINESS WIRE)--Pfizer Inc announced today that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg. This finding is from a subanalysis designed and completed following the closure of the five-year Treating to New Targets (TNT) study in

BUSINESS WIRE)--Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer’s disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31. Pfizer will also host an analyst briefing at ICAD

(BUSINESS WIRE)--Pfizer announced today that new statin users who took Lipitor® (atorvastatin calcium) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an observational study of more than 186,000 patients in one of the largest U.S. managed care claims databases. The results were published in the July issue of Current Medical Research and Opinion. “It is